ITD-1 potently blocks phosphorylation of the effector SMAD2/3 proteins induced by TGFβ2. ITD-1 strongly inhibits TGFβ2 signaling with similar efficacy (92% vs. 99% respectively), but with lower potency compared to SB-431542, an ACVR1B/TGFBR1 kinase inhibitor (IC50= 850nM vs. 70nM respectively), and is a weak and partial inhibitor of Activin A signals. ITD-1 selectively enhances the differentiation of uncommitted mesoderm to cardiomyocytes, but not to vascular smooth muscle and endothelial cells.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥ 50 mg/mL|
|Related TGF-beta/Smad Products|
BIBF0775 is a potent and selective inhibitor of the transforming growth factor β receptor I (TGFβRI, Alk5) with an IC50 of 34 nM.
SB-4 is a potent benzoxazole bone morphogenetic protein 4 (BMP4) signaling agonist with a EC50 value of 74 nM.
SJ000291942 is a bone morphogenic protein (BMP) signaling activator.
SM16 inhibits TGFβ-induced plasminogen activator inhibitor-luciferase activity (IC50=64 nM).
SRI-011381 is an agonist of the TGF-beta signaling pathway for treatment of Alzheimer's disease.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.